StockData
MacroGenics Inc logo

MacroGenics Inc (MGNX) stock

MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.97−0.08 (-3.90%)

Close on Nov 18, 2026Market cap $125.49MP/E –Yield –

MacroGenics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

MacroGenics's operating income for the twelve months ending Jun 30, 2026 was -$40.75M. For fiscal 2025 it was -$72.84M. The highest annual figure on record is $8.21M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$72.84M–
FY2024Dec 31, 2024-$110.58M–
FY2023Dec 31, 2023-$168.24M–
FY2022Dec 31, 2022-$121.42M–
FY2021Dec 31, 2021-$202.80M–
FY2020Dec 31, 2020-$131.06M–
FY2019Dec 31, 2019-$177.19M–
FY2018Dec 31, 2018-$171.21M–
FY2017Dec 31, 2017-$22.14M–
FY2016Dec 31, 2016-$60.04M–
FY2015Dec 31, 2015-$20.18M–
FY2014Dec 31, 2014-$38.32M-10568.6%
FY2013Dec 31, 2013$366.00K-95.5%
FY2012Dec 31, 2012$8.21M+56.3%
FY2011Dec 31, 2011$5.25M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.85M–
Q1 FY2026Mar 31, 2026-$33.44M–
Q4 FY2025Dec 31, 2025-$12.10M–
Q3 FY2025Sep 30, 2025$18.64M-65.6%
Q2 FY2025Jun 30, 2025-$43.22M–
Q1 FY2025Mar 31, 2025-$42.62M–
Q4 FY2024Dec 31, 2024-$52.84M–
Q3 FY2024Sep 30, 2024$54.19M–
Q2 FY2024Jun 30, 2024-$58.18M–
Q1 FY2024Mar 31, 2024-$53.75M–
Q4 FY2023Dec 31, 2023-$49.35M-511.9%
Q3 FY2023Sep 30, 2023-$35.50M–
Q2 FY2023Jun 30, 2023-$44.96M–
Q1 FY2023Mar 31, 2023-$38.43M–
Q4 FY2022Dec 31, 2022$11.98M–
Q3 FY2022Sep 30, 2022-$24.96M–
Q2 FY2022Jun 30, 2022-$41.81M–
Q1 FY2022Mar 31, 2022-$66.64M–
Q4 FY2021Dec 31, 2021-$58.24M–
Q3 FY2021Sep 30, 2021-$52.99M–
Q2 FY2021Jun 30, 2021-$40.28M–
Q1 FY2021Mar 31, 2021-$51.29M–
Q4 FY2020Dec 31, 2020-$2.17M–
Q3 FY2020Sep 30, 2020-$36.14M–
Q2 FY2020Jun 30, 2020-$47.31M–
Q1 FY2020Mar 31, 2020-$45.45M–
Q4 FY2019Dec 31, 2019-$38.66M–
Q3 FY2019Sep 30, 2019-$37.94M–
Q2 FY2019Jun 30, 2019-$52.97M–
Q1 FY2019Mar 31, 2019-$47.62M–
Q4 FY2018Dec 31, 2018-$41.68M-139.7%
Q3 FY2018Sep 30, 2018-$35.00M–
Q2 FY2018Jun 30, 2018-$44.31M–
Q1 FY2018Mar 31, 2018-$50.21M–
Q4 FY2017Dec 31, 2017$104.97M–
Q3 FY2017Sep 30, 2017-$47.72M–
Q2 FY2017Jun 30, 2017-$41.18M–
Q1 FY2017Mar 31, 2017-$38.21M–
Q4 FY2016Dec 31, 2016-$35.24M–
Q3 FY2016Sep 30, 2016-$34.27M–

More MacroGenics figures

See a number that looks wrong?